Clinical trials: HIV Antibodies
HIV Infections, HIV Seronegativity
A Study of GENEVAX-HIV, a Possible Vaccine
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug…
- Trial name
- NCT00002232
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
Human Immunodeficiency Virus
3BNC117-LS First-in-Human Phase 1 Study
The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are…
- Trial name
- NCT03254277
- Testing
- 3BNC117-LS
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
To assess the safety and immune response to two experimental vaccines when formulated with QS-21 or QS-21 plus alum. To determine whether the new preparation of QS-21 in polysorbate 80 is less reactogenic than the QS-21…
- Trial name
- NCT00001096
- Testing
- MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
Adult participants (18-64 years old) with HIV-1 Infection on ART with a CD4 T cell count ≥ 350 cells/mm3 and viral suppression for ≥ 24 months will be enrolled on this study.
- Trial name
- NCT03803605
- Testing
- VRC07-523LS, Vorinostat (VOR)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
Participants will receive an infusion of both study drugs (3BNC117-LS and 10-1074-LS) and will discontinue antiretroviral therapy (which is the treatment for HIV) two days later.
- Trial name
- NCT05079451
- Testing
- 3BNC117-LS, 10-1074-LS
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda
The purpose of this study is to see if it is safe to give ALVAC-HIV vCP205, a possible HIV vaccine, and to study the immune responses in adult HIV-1 uninfected volunteers.
- Trial name
- NCT00007423
- Testing
- ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65)
- Where
- 2 sites in Uganda
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Geriatric Medicine
COVID-19 Serology and Immunosenescence
This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors.
- Conditions
- Covid19, Geriatric Medicine, Seroconversion, Immunosenescence
- Trial name
- SERO-CoV-OLD (NCT04563650)
- Testing
- blood sample
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
HIV-1-infection
Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine
ACTHIVE-001 is a randomised, open-label, uncontrolled phase 1 clinical trial to determine the safety profile of the native-like HIV-1 envelope vaccine, ConM SOSIP.v7, adjuvanted with monophosphoryl lipid A (MPLA) liposomes.
- Trial name
- ACTHIVE-001 (NCT03961438)
- Testing
- ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
HIV Infections, HIV Seronegativity
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection.
- Trial name
- NCT00006298
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy
The purpose of this study was to evaluate the safety and antiviral activity to promote clearance of HIV-1 infected cells of VRC01 in infants with HIV beginning combination antiretroviral therapy (cART).
- Trial name
- NCT03208231
- Testing
- VRC01, Combination Antiretroviral Therapy (cART)
- Where
- 7 sites in Botswana, Brazil and 2 more
- Volunteers
- 61 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, SARS-CoV-2 Infection
COVID-19 Serology in People Living with HIV in Hong Kong
Immunodeficiency associated with human immunodeficiency virus (HIV) infection could predispose people living with HIV/AIDS (PLHA) to defective serological responses following infection or vaccination.
- Conditions
- HIV Infections, SARS-CoV-2 Infection, Vaccination; Infection
- Trial name
- NCT05028881
- Testing
- blood sampling
- Where
- China
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Human Immunodeficiency Virus
Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women
A Phase I Single-Blind randomised trial investigating immunisation strategies using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA combinations in order to maximise antibody responses to Human Immunodeficiency Virus
- Trial name
- Ad4HIV (NCT03408262)
- Testing
- Ad4-EnvCN54, MVA-CN54, CN54gp140/MPLA
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HIV Infections
Immune Response to Influenza Vaccine in HIV-Infected Individuals
This study will evaluate how HIV infection, including CD4 cell count and viral load, affects the patient's ability to produce antibodies in response to vaccination with the influenza (flu) vaccine.
- Trial name
- NCT00069914
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria
To determine the safety, tolerance, and potential in vivo antiviral effects of five dosage levels and a dose to be determined of human anti-cytomegalovirus (CMV) monoclonal antibody (SDZ MSL-109; formerly SDZ 89-109) when…
- Trial name
- NCT00002268
- Testing
- Sevirumab
- Where
- 2 sites in United States
- Sponsor
- Sandoz
Acute HIV Infection
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: Administration of…
- Trial name
- NCT05719441
- Testing
- VRC07-523LS, PGT121.414.LS, ART
- Where
- 12 sites in United States, Brazil and 1 more
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Evaluation Study of RDTs Detecting Antibodies Against HCV
The study aims to evaluate 13 different HCV RDTs (10 on-market, 3 under development) for their diagnostic performance and operational characteristics in archived EDTA plasma samples, originating from patients from different…
- Trial name
- NCT04033887
- Testing
- 13 Rapid Diagnostic Tests and reference tests
- Where
- 3 sites in Belgium, Georgia and 1 more
- Volunteers
- 1,710 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
HIV Infections
Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy
This is a phase 1, randomized, placebo-controlled, dose-escalation study of CCR5mAb004 in HIV-1 seropositive individuals who are not receiving concurrent antiretroviral therapy.
- Trial name
- NCT00114699
- Testing
- CCR5mAb004
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Human Genome Sciences Inc.
Lymphoma
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without monoclonal antibody therapy in treating patients who have previously untreated HIV-associated non-Hodgkin's lymphoma.
- Trial name
- NCT00003595
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1 Infected Adults With Controlled Viremia
Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial
Background: The Human Immunodeficiency Virus (HIV) attacks the immune system. Scientists have created a gene that could be transferred to the cells of people with HIV.
- Trial name
- VRC 603 (NCT03374202)
- Testing
- VRC-HIVAAV070-00-GT (AAV8-VRC07)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anti-r-HuEpo Associated PRCA Subjects
Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment
Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve morbidity and mortality in chronic kidney disease.
- Trial name
- NCT01288131
- Testing
- Cyclosporine combine with mycophenolate mofetil, Cyclophosphamide + pred
- Where
- Thailand
- Volunteers
- 8 people
- Sponsor
- Chulalongkorn University